Shigella Vaccine Candidate Shows 89% Efficacy in Phase 2 Trial — Cincinnati Children's Hospital Medical Center

Event summary

Cincinnati Children's Hospital Medical Center led a phase 2 trial for the WRSs2 Shigella vaccine candidate, showing 89% efficacy against Shigella sonnei.
The oral vaccine demonstrated reduced symptom severity and lower bacterial shedding in vaccinated participants.
Trial enrolled 108 healthy adults aged 18 to 49 between October 2022 and January 2024, with 73 completing the challenge phase.
No serious adverse events were reported, supporting a favorable safety profile.

The big picture

The success of the WRSs2 vaccine trial marks a significant milestone in combating Shigella, a disease responsible for millions of infections and thousands of deaths annually. With no approved vaccine currently available, this development could address growing antibiotic resistance and reduce transmission risks in vulnerable populations. The collaboration between academic, military, and government research teams underscores the strategic importance of this breakthrough.

What we're watching

Clinical Progression: Whether WRSs2 can replicate efficacy in larger trials, particularly among high-risk pediatric populations.
Regulatory Pathway: The pace at which the vaccine candidate advances through subsequent clinical phases and potential FDA approval.
Market Impact: How successful commercialization could affect global health outcomes, particularly in regions with high Shigella prevalence.